Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
11 hedge funds and large institutions have $11.4M invested in Virpax Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
925% more capital invested
Capital invested by funds: $1.12M → $11.4M (+$10.3M)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
83% more funds holding
Funds holding: 6 → 11 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$7.02M |
| 2 |
KC
Kepos Capital
New York
|
+$6.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.34M |
| 4 |
ACM
Altium Capital Management
New York
|
+$2.28M |
| 5 |
Two Sigma Investments
New York
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$205K |
| 2 |
VF
Virtu Financial
New York
|
-$83.8K |
| 3 |
SC
Saltoro Capital
Dallas,
Texas
|
-$80K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $4.77M | +$7.02M | +3,353 | +542% |
|
|
KC
2
Kepos Capital
New York
| $3.6M | +$6.28M | +3,000 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $1.34M | +$2.34M | +1,116 | New |
|
|
ACM
4
Altium Capital Management
New York
| $1.3M | +$2.28M | +1,087 | New |
|
|
5
Two Sigma Investments
New York
| $123K | +$216K | +103 | New |
|
6
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $93K | +$163K | +78 | New |
|
|
BRWA
7
B. Riley Wealth Advisors
Boca Raton,
Florida
| $90K | +$155K | +74 | New |
|
|
VF
8
Virtu Financial
New York
| $66K | -$83.8K | -40 | -42% |
|
9
Geode Capital Management
Boston,
Massachusetts
| $48K | +$83.8K | +40 | New |
|
10
Morgan Stanley
New York
| $11K | +$12.6K | +6 | +200% |
|
11
Wells Fargo
San Francisco,
California
| $3K | +$4.19K | +2 | New |
|
|
ZCA
12
Zeke Capital Advisors
Berwyn,
Pennsylvania
| – | -$205K | -180 | Closed |
|
|
SC
13
Saltoro Capital
Dallas,
Texas
| – | -$80K | -70 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$18K | -16 | Closed |
|
VRPX Hedge Fund Activity: Q3 2021 in Review
11 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q3 2021, worth a combined $11.4M — up 925% from $1.12M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VRPX positions and 3 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, adding an estimated $7.02M. The largest seller was Zeke Capital Advisors, exiting entirely with an estimated $205K sold.
- 11 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q3 2021, up from 6 in Q2 2021.
- Funds reported $11.4M of Virpax Pharmaceuticals, Inc. Common Stock stock for Q3 2021, up 925% quarter-over-quarter.
- 8 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +5 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Sabby Management, an estimated $7.02M added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Zeke Capital Advisors, an estimated $205K sold.
Based on aggregated 13F filings for Q3 2021.